PROJECT 12. Protocal Review

项目 12. 协议审查

• 批准号: 9304075
• 负责人: John Hayslip
• 金额: $ 11.16万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9304075
• 关键词: Appalachian Region; Area; Basic Science; Behavioral Sciences; Cancer Center; Cancer Center Support Grant; Cancer Intervention; Charge; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials; Colorectal Cancer; Development; Documentation; England; Ensure; Equilibrium; Future; Incidence; Instruction; Kentucky; Lead; Malignant Neoplasms; Malignant neoplasm of lung; Medical center; Monitor; Patient Care; Patients; Population Heterogeneity; Population Sciences; Poverty; Process; Protocols documentation; Research Personnel; Resource Sharing; Resources; Risk Behaviors; Services; Smoking; System; Therapeutic Human Experimentation; Translational trial; United States; Universities; anticancer research; authority; cancer survival; clinical translation; data management; health disparity; novel; operation; patient oriented; research study; screening

The Markey Cancer Center (MCC) Protocol Review and Monitoring System (PRMS) provides thorough review of clinical trials for scientific validity, feasibility and prioritization within the clinical trials portfolio and monitoring of scientific progress. The PRMS must approve all interventional cancer research prior to study initiation and has the authority to recommend closure of trials for lack of scientific progress or patient accrual. The PRMS provides a framework which aims to balance appropriate resource utilization while maximizing the opportunities for current and future patients with cancer in this region to participate in clinical trials, including the underserved area of Appalachian Kentucky. The development of novel MCC investigator-initiated clinical trials and participation in high-priority national trials provide a robust portfolio of therapeutic research studies available to MCC patients.

马基癌症中心 (MCC) 方案审查和监测系统 (PRMS) 提供了全面的 审查临床试验的科学有效性、可行性和临床试验组合中的优先顺序，以及 监测科学进步。 PRMS 必须在研究之前批准所有介入癌症研究 启动并有权因缺乏科学进展或患者应计情况而建议结束试验。 PRMS 提供了一个框架，旨在平衡适当的资源利用，同时最大化 该地区当前和未来的癌症患者参与临床试验的机会， 包括肯塔基州阿巴拉契亚地区服务欠缺的地区。研究者发起的新型 MCC 开发 临床试验和参与高度优先的国家试验提供了强大的治疗组合 可供 MCC 患者使用的研究。